Geron Stem Cell Trial Risky, Doctors Warn

<p>Geron’s(GERN Quote – Cramer on GERN – Stock Picks) upcoming and widely publicized stem cell trial involving patients with spinal cord injuries was criticized as risky and clinically dubious because the entire rationale for the study is &quot;based on a single experiment in eight rats.&quot;</p> <p>More on GERN M&amp;A Flurry Can’t Lift MarketStock Search: Merck and Shering Plough Fail To Spark The MarketsStock Wrap: The Real Story March 93 Stocks I Saw on TVBiotech Stock Mailbag: Geron GambitGeron’s Stem-Cell Research Hype Soaks InvestorsGeron’s a Slow-Go, Not a No-GoU.S. Steel, American Express Gird StocksFour Must-See Charts of the Day: Small-Cap Stocks to WatchCAT Can’t Scratch Indices Market Activity Aastrom Biosciences Incorporated| ASTM UPThe negative view of Geron’s research effort came from a spinal surgeon and stem cell researcher during a conference call for institutional investors held Monday by Summer Street Research Partners, an independent health care research firm…</p>